Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas.

about

Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas.

Item

http://www.wikidata.org/entity/Q36927640

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Phase II Study of a Non-Platin ...... Advanced Lung Adenocarcinomas.

@en

type

Item

label

Phase II Study of a Non-Platin ...... Advanced Lung Adenocarcinomas.

@en

prefLabel

Phase II Study of a Non-Platin ...... Advanced Lung Adenocarcinomas.

@en

P1476

Phase II Study of a Non-Platin ...... Advanced Lung Adenocarcinomas.

@en

P2093

Ethan M Basch

http://www.w3.org/2001/XMLSchema#string

John J Fiore

http://www.w3.org/2001/XMLSchema#string

Lauren J Rogak

http://www.w3.org/2001/XMLSchema#string

Lawrence H Schwartz

http://www.w3.org/2001/XMLSchema#string

M C Pietanza

http://www.w3.org/2001/XMLSchema#string

Mark G Kris

http://www.w3.org/2001/XMLSchema#string

Marwan Shouery

http://www.w3.org/2001/XMLSchema#string

Mary Shaw

http://www.w3.org/2001/XMLSchema#string

Matthew D Hellmann

http://www.w3.org/2001/XMLSchema#string

Michelle S Ginsberg

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

Harnessing technology to improve clinical trials: study of real-time informatics to collect data, toxicities, image response assessments, and patient-reported outcomes in a phase II clinical trial.

Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial.

Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.

A case series of dose-limiting peripheral edema observed in patients treated with pemetrexed.

PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-s

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

P304

890-899

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JTHO.2016.02.018

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Alex Lash

P577

2016-03-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

297661983

http://www.w3.org/2001/XMLSchema#string

P698

26964771

http://www.w3.org/2001/XMLSchema#string

P921

adenocarcinoma

bevacizumab

P932

4877255

http://www.w3.org/2001/XMLSchema#string